Home > Insider Trading > Filing (0001127602-17-016142)

Filing Details

Accession Number:: 0001127602-17-016142
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-05-01 17:47:49
Reporting Period:: 2017-04-27

Filing Date:: 2017-05-01
Accepted Time:: 2017-05-01 17:47:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875045	Biogen Inc.	BIIB	Biological Products, (No Disgnostic Substances) (2836)	330112644

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1361754	J Alexander Denner	Biogen Inc. 225 Binney Street Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-04-27	15,000	$278.58	325,000	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2017-04-27	58,858	$278.48	383,858	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	8,974	Direct

Footnotes

On April 27, 2017, Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic"), purchased an aggregate of 73,858 shares of common stock of Biogen Inc.
Includes (i) 205,142 shares beneficially owned by Sarissa Domestic and (ii) 119,858 shares beneficially owned by Sarissa Capital Offshore Master Fund LP, a Cayman Island exempted limited partnership ("Sarissa Offshore" and together with Sarissa Domestic, the "Sarissa Funds"). Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds.
Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownerhip of these shares except to the extent of his pecuniary interest therein.
Includes (i) 264,000 shares beneficially owned by Sarissa Domestic and (ii) 119,858 shares beneficially owned by Sarissa Offshore.
On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.